Skip to main content

Advertisement

Fig. 2 | BMC Medicine

Fig. 2

From: Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer

Fig. 2

Network of 77 randomized controlled trials of second-line treatments in advanced non-small cell lung cancer. The thickness of connecting lines indicates the number of available comparisons. The size of each node is proportional to the number of patients allocated to the corresponding treatment. AFL: aflibercept; AMR: amrubicin; ARQ197: tivantinib; BEV: bevacizumab; BIBF1120: nintedanib; BSC: best supportive care; CET: cetuximab; DAC: dacomitinib; DOC: docetaxel; ERL: erlotinib; EVE: everolimus; FIGI: figitumumab; FULV: fulvestrant; GEF: gefitinib; ICO: icotinib; MAT: matuzumab; MK-0646: dalotuzumab; ONA: onartuzumab; PAZ: pazopanib; PBO: placebo; PDX: pralatrexate; PEM: pemetrexed; PTX: paclitaxel; RAM: ramucirumab; SEL: selumetinib; SOR: sorafenib; SUN: sunitinib; TOP: topotecan; TRA: trametinib; VAN: vandetanib; VFL: vinflunine; VIN: vinorelbine

Back to article page